GRAIL Announces Collaboration With U.S. Department of Veterans Affairs and the Veterans Health Foundation to Evaluate Galleri Multi-Cancer Early Detection Test
Collaboration Will Provide Galleri Test to 10,000 Veterans Across the U.S. Over the Next Three Years; VA Pittsburgh Healthcare System Announced as First of Approximately 10 Participating Sites
Collaboration is Part of REFLECTION, a Real-World Observational Study Evaluating Performance of Galleri in Clinical Settings
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced a collaboration with the U.S. Department of Veterans Affairs (VA) Veterans Health Administration, America’s largest integrated health care system, and the Veterans Health Foundation to provide Galleri, GRAIL’s groundbreaking multi-cancer early detection (MCED) blood test, to 10,000 veterans across approximately 10 participating VA sites over the next three years. The VA Pittsburgh Healthcare System is the first VA site that will be participating.
Latest Aithority Insights: Top Skills Needed to Become an AI Engineer
“We are thrilled to collaborate with the VA, the Veterans Health Foundation and U.S. veterans for this important real-world evaluation of the Galleri test and its potential to transform early cancer detection,” said Bob Ragusa, CEO of GRAIL.
Through the collaboration, eligible U.S. military veterans will be able to receive the Galleri test and can enroll in GRAIL’s REFLECTION registry, an observational, multi-center, real-world evidence study. REFLECTION will assess Galleri’s performance, when combined with recommended cancer screenings, to find earlier cancer in the population, when there is a higher chance of successful and potentially curative treatment. REFLECTION will enroll 35,000 healthy volunteers and evaluate the performance of Galleri in diverse clinical settings as part of routine medical care.
Browse The Complete News About Aithority : One AI to Take on Global Language AI Challenge with NLP-as-a-service Platform for Developers
“Cancer is a significant issue for U.S. veterans, many of whom are at high risk,” said Dr. Charles Atwood, pulmonologist and lead researcher on the REFLECTION study at VA Pittsburgh. “GRAIL’s multi-cancer early detection test will be provided to veterans, in addition to current recommended screenings, with the aim of improving early diagnoses and outcomes.”
The Galleri test is a first-of-its-kind MCED blood test. In a clinical study, the Galleri test demonstrated the ability to detect signals across more than 50 types of cancers, over 45 of which lack recommended screening tests today. Using advanced genomics and machine learning, the test also determines the origin of the cancer signal, which can then guide diagnostic workup. Early detection of cancer is known to improve cancer outcomes, yet today, the majority of cancers are detected in late stages because only five cancer types have recommended screenings – breast, cervical, colon, lung and prostate cancers.
“As the largest national integrated health system in the U.S., the VA delivers unparalleled care to our veterans, many of whom are at elevated risk of developing cancer. We are thrilled to collaborate with the VA, the Veterans Health Foundation and U.S. veterans for this important real-world evaluation of the Galleri test and its potential to transform early cancer detection,” said Bob Ragusa, chief executive officer at GRAIL. “Together, we hope participation in the REFLECTION registry study and receiving a Galleri test will lead to more cancer diagnoses at an earlier stage, when treatment is more likely to be successful.”
Nationwide, 1.2 million veterans who have used VA health care since the beginning of fiscal year 2021 have received a cancer diagnosis. That number includes 14 percent of veterans treated at VA Pittsburgh in the same time frame.
Read More About Aithority News : Fraud Mitigation Receives a Boost with SEON’s ML-based Blackbox Update
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.